Understand the source comparison
SS-31 Science Explained: Clinical Trial Design Comparison
| Trial / Study Type | Primary Endpoint | Dose / Route | Population | Outcome Measure | Result Summary | Bottom Line ||—|—|—|—|—|—|| EMBRACE STEMI-AMI (Phase II) | Infarct size as % of LV mass at 4 days post-MI | 0.05 mg/kg IV bolus + 1.25 mg/kg/hr × 1 hr befo
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Trial / Study Type | Primary Endpoint | Dose / Route | Population | Outcome Measure | Result Summary | Bottom Line ||—|—|—|—|—|—|| EMBRACE STEMI-AMI (Phase II) | Infarct size as % of LV mass at 4 days post-MI | 0.05 mg/kg IV bolus + 1.25 mg/kg/hr × 1 hr before PCI | 297 STEMI patients undergoing PCI | Cardiac MRI T2-weighted imaging | No significant difference in intention-to-treat; 20% reduction in <4hr subgroup (p=0.02) | Therapeutic window matters. Early intervention shows benefit || Phase II Heart Failure (HFpEF) | Change in peak VO2 at 28 weeks | 4 mg/day subcutaneous injection | Heart failure with preserved ejection fraction | Cardiopulmonary exercise testing | 1.5 mL/kg/min improvement in peak VO2 vs placebo (not statistically significant) | Trend toward improved exercise capacity; requires larger trial || Preclinical Aging Model (Mice) | Exercise capacity (treadmill time to exhaustion) | 3 mg/kg/day subcutaneous × 8 weeks | 24-month-old C57BL/6 mice | Treadmill endurance test